These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

153 related items for PubMed ID: 11806987

  • 1. Monitoring of minimal residual disease after CHOP and rituximab in previously untreated patients with follicular lymphoma.
    Rambaldi A, Lazzari M, Manzoni C, Carlotti E, Arcaini L, Baccarani M, Barbui T, Bernasconi C, Dastoli G, Fuga G, Gamba E, Gargantini L, Gattei V, Lauria F, Lazzarino M, Mandelli F, Morra E, Pulsoni A, Ribersani M, Rossi-Ferrini PL, Rupolo M, Tura S, Zagonel V, Zaja F, Zinzani P, Reato G, Foa R.
    Blood; 2002 Feb 01; 99(3):856-62. PubMed ID: 11806987
    [Abstract] [Full Text] [Related]

  • 2. Quantitative PCR of bone marrow BCL2/IgH+ cells at diagnosis predicts treatment response and long-term outcome in follicular non-Hodgkin lymphoma.
    Rambaldi A, Carlotti E, Oldani E, Della Starza I, Baccarani M, Cortelazzo S, Lauria F, Arcaini L, Morra E, Pulsoni A, Rigacci L, Rupolo M, Zaja F, Zinzani PL, Barbui T, Foa R.
    Blood; 2005 May 01; 105(9):3428-33. PubMed ID: 15637137
    [Abstract] [Full Text] [Related]

  • 3. Phase II study of CHOP-GR therapy for advanced-stage follicular lymphoma.
    Tomita N, Kodama F, Oshima R, Hashimoto C, Koharazawa H, Takemura S, Yamazaki E, Fujimaki K, Sakai R, Fujita H, Fujisawa S, Kanamori H, Motomura S, Ishigatsubo Y.
    Leuk Lymphoma; 2006 Jun 01; 47(6):1041-7. PubMed ID: 16840195
    [Abstract] [Full Text] [Related]

  • 4. Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival.
    Howard OM, Gribben JG, Neuberg DS, Grossbard M, Poor C, Janicek MJ, Shipp MA.
    J Clin Oncol; 2002 Mar 01; 20(5):1288-94. PubMed ID: 11870171
    [Abstract] [Full Text] [Related]

  • 5. Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as front-line treatment for patients with follicular lymphoma.
    Zinzani PL, Pulsoni A, Perrotti A, Soverini S, Zaja F, De Renzo A, Storti S, Lauta VM, Guardigni L, Gentilini P, Tucci A, Molinari AL, Gobbi M, Falini B, Fattori PP, Ciccone F, Alinari L, Martelli M, Pileri S, Tura S, Baccarani M.
    J Clin Oncol; 2004 Jul 01; 22(13):2654-61. PubMed ID: 15159414
    [Abstract] [Full Text] [Related]

  • 6. Rituximab (anti-CD20 monoclonal antibody) as consolidation of first-line CHOP chemotherapy in patients with follicular lymphoma: a phase II study.
    Jäeger G, Neumeister P, Brezinschek R, Höfler G, Quehenberger F, Linkesch W, Sill H.
    Eur J Haematol; 2002 Jul 01; 69(1):21-6. PubMed ID: 12270058
    [Abstract] [Full Text] [Related]

  • 7. Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma.
    Vose JM, Link BK, Grossbard ML, Czuczman M, Grillo-Lopez A, Gilman P, Lowe A, Kunkel LA, Fisher RI.
    J Clin Oncol; 2001 Jan 15; 19(2):389-97. PubMed ID: 11208830
    [Abstract] [Full Text] [Related]

  • 8. High-dose therapy and autologous bone marrow transplantation in patients with follicular lymphoma during first remission.
    Freedman AS, Gribben JG, Neuberg D, Mauch P, Soiffer RJ, Anderson KC, Pandite L, Robertson MJ, Kroon M, Ritz J, Nadler LM.
    Blood; 1996 Oct 01; 88(7):2780-6. PubMed ID: 8839876
    [Abstract] [Full Text] [Related]

  • 9. Clearing of cells bearing the bcl-2 [t(14;18)] translocation from blood and marrow of patients treated with rituximab alone or in combination with CHOP chemotherapy.
    Czuczman MS, Grillo-López AJ, McLaughlin P, White CA, Saleh M, Gordon L, LoBuglio AF, Rosenberg J, Alkuzweny B, Maloney D.
    Ann Oncol; 2001 Jan 01; 12(1):109-14. PubMed ID: 11249036
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma: five-year follow-up of Southwest Oncology Group Protocol S9911.
    Press OW, Unger JM, Braziel RM, Maloney DG, Miller TP, Leblanc M, Fisher RI, Southwest Oncology Group.
    J Clin Oncol; 2006 Sep 01; 24(25):4143-9. PubMed ID: 16896003
    [Abstract] [Full Text] [Related]

  • 12. One single dose of rituximab added to a standard regimen of CHOP in primary treatment of follicular lymphoma appears to result in a high clearance rate from circulating bcl-2/IgH positive cells: Is the end of molecular monitoring near?
    Schmitt C, Grundt A, Buchholtz C, Scheuer L, Benner A, Hensel M, Ho AD, Leo E.
    Leuk Res; 2006 Dec 01; 30(12):1563-8. PubMed ID: 16530831
    [Abstract] [Full Text] [Related]

  • 13. The addition of rituximab to CHOP chemotherapy improves overall and failure-free survival for follicular grade 3 lymphoma.
    Overman MJ, Feng L, Pro B, McLaughlin P, Hess M, Samaniego F, Younes A, Romaguera JE, Hagemeister FB, Kwak L, Cabanillas F, Rodriguez MA, Fayad LE.
    Ann Oncol; 2008 Mar 01; 19(3):553-9. PubMed ID: 18083690
    [Abstract] [Full Text] [Related]

  • 14. A phase 2 trial of CHOP chemotherapy followed by tositumomab/iodine I 131 tositumomab for previously untreated follicular non-Hodgkin lymphoma: Southwest Oncology Group Protocol S9911.
    Press OW, Unger JM, Braziel RM, Maloney DG, Miller TP, LeBlanc M, Gaynor ER, Rivkin SE, Fisher RI.
    Blood; 2003 Sep 01; 102(5):1606-12. PubMed ID: 12738671
    [Abstract] [Full Text] [Related]

  • 15. FcgammaRIIIA and FcgammaRIIA polymorphisms do not predict clinical outcome of follicular non-Hodgkin's lymphoma patients treated with sequential CHOP and rituximab.
    Carlotti E, Palumbo GA, Oldani E, Tibullo D, Salmoiraghi S, Rossi A, Golay J, Pulsoni A, Foà R, Rambaldi A.
    Haematologica; 2007 Aug 01; 92(8):1127-30. PubMed ID: 17650444
    [Abstract] [Full Text] [Related]

  • 16. Continued Excellent Outcomes in Previously Untreated Patients With Follicular Lymphoma After Treatment With CHOP Plus Rituximab or CHOP Plus 131I-Tositumomab: Long-Term Follow-Up of Phase III Randomized Study SWOG-S0016.
    Shadman M, Li H, Rimsza L, Leonard JP, Kaminski MS, Braziel RM, Spier CM, Gopal AK, Maloney DG, Cheson BD, Dakhil S, LeBlanc M, Smith SM, Fisher RI, Friedberg JW, Press OW.
    J Clin Oncol; 2018 Mar 01; 36(7):697-703. PubMed ID: 29356608
    [Abstract] [Full Text] [Related]

  • 17. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy.
    Czuczman MS, Grillo-López AJ, White CA, Saleh M, Gordon L, LoBuglio AF, Jonas C, Klippenstein D, Dallaire B, Varns C.
    J Clin Oncol; 1999 Jan 01; 17(1):268-76. PubMed ID: 10458242
    [Abstract] [Full Text] [Related]

  • 18. Rituximab plus short-duration chemotherapy as first-line treatment for follicular non-Hodgkin's lymphoma: a phase II trial of the minnie pearl cancer research network.
    Hainsworth JD, Litchy S, Morrissey LH, Andrews MB, Grimaldi M, McCarty M, Greco FA.
    J Clin Oncol; 2005 Mar 01; 23(7):1500-6. PubMed ID: 15632411
    [Abstract] [Full Text] [Related]

  • 19. Combined treatment with anti-CD20 (rituximab) and CHOP in relapsed advanced-stage follicular lymphomas.
    Domingo-Domènech E, González-Barca E, Estany C, Sureda A, Besalduch J, Fernández de Sevilla A.
    Haematologica; 2002 Nov 01; 87(11):1229-30. PubMed ID: 12414357
    [Abstract] [Full Text] [Related]

  • 20. Immunotherapy with rituximab following high-dose therapy and autologous stem-cell transplantation for mantle cell lymphoma.
    Mangel J, Buckstein R, Imrie K, Spaner D, Crump M, Tompkins K, Reis M, Perez-Ordonez B, Deodhare S, Romans R, Pennell N, Robinson JB, Hewitt K, Richardson P, Lima A, Pavlin P, Berinstein NL.
    Semin Oncol; 2002 Feb 01; 29(1 Suppl 2):56-69. PubMed ID: 11842390
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.